Archer-Daniels-Midland Company (NYSE: ADM) — The Recovery Bought Before It Arrived: A Cyclical Earning Its Cost of Capital, Re-Rated on Trough Earnings

Independent fundamental research. As-of date: 2026-06-26. Price referenced: $76.79 (NYSE close, 2026-06-26).

⚡ Claude’s Take

This block is the author’s own independent opinion, included as a single, clearly-labeled view. It is general information, not investment advice. The analysis that follows takes no position and carries no price target.

Verdict: HOLD / not-a-buy-here. Accumulate only on weakness in the low-$50s–high-$50s (≈1.1–1.3× book, ≈10–11× mid-cycle EPS). Not a short. Fair-value zone ≈ $58–68. Conviction: medium. Tag: “The recovery bought before it arrived.”

ADM is a structurally average business — a capital-intensive commodity processor whose through-cycle return on invested capital (≈7%) barely clears its cost of capital, whose “moat” is scale and asset-network barriers to entry with no barrier to competition, and whose one attempt to build a differentiated, higher-margin franchise (the Nutrition roll-up around the $3B 2014 WILD Flavors deal) destroyed value and became the locus of a 2024 accounting scandal. None of that is a reason to short it: the balance sheet is sound, it is a 52-year Dividend King yielding ~2.7%, and at a genuine earnings trough the downside is cushioned. But the stock has already done the work the bulls are waiting for. From a washed-out ~$39 low in April 2025 it has rallied ~95% to $77 — a pure multiple-repair leg, because earnings have not yet recovered (FY2025 GAAP EPS was $2.23, the cycle trough; ADM’s own FY2026 adjusted EPS guide is just $4.15–4.70). At $77 on ~$45B EV the market is already underwriting roughly $5.50–6.00 of mid-cycle EPS and a normalized crush/ethanol environment — i.e., the recovery is largely in the price before it is in the P&L.

The framing is a low-beta (0.33) Value-and-Dividend name that was abandoned and has re-rated — momentum-up off a bombed-out base, not a falling knife and not a crowded momentum trade. That matters: the easy money (the de-rating reversal) is made. What’s left requires mid-cycle EBITDA to actually show up — soybean crush spreads to widen durably on 45Z renewable-diesel demand, ethanol to hold, China offtake to normalize — against a tougher backdrop of post-2021 crush over-capacity and a newly-merged, deeper-pocketed Bunge-Viterra. I’d own it as a cheap-cyclical/income sleeve bought in the $50s, not chased at $77. Flips bullish if FY2026 adjusted EPS prints above ~$5 with crush spreads widening into 2027 and Adjusted ROIC climbing back toward double digits. Flips bearish if FY2026 EPS lands below ~$4.15, crush rolls back over in 2H, or a fresh leg of the SEC/governance matter surfaces.

📈 Stock Price Action — Five-Year Event Map

Factual five-year price history with attributed drivers. Price moves are FACT; attributed causes are INTERPRETATION. No recommendation, no price target — the opportunity judgment lives in Claude’s Take above.

ADM has completed a full round-trip and then some over five years: from ~$53 in mid-2021, up to a nominal all-time high near $97 (≈$86 split/dividend-adjusted) in November 2022 on the commodity/crush boom, down through a two-year grind to a $39 low in April 2025, and back up ~95% to $76.79 today — roughly 22% below the 2022 high. The 52-week range is $49.77–$82.56. The defining feature of the chart is that the entire 2025–26 rally is a valuation move: it happened while reported earnings were still falling to and sitting at a cycle trough.

Cycle narrative. (1) The 2021–22 run was a textbook agricultural-commodity boom — tight global grain balances and a war-driven price spike lifted both volumes and processing spreads, and ADM printed its best two years ever. (2) As global supply normalized, crush and merchandising margins reverted and the stock gave back roughly a third. (3) The single most important price event of the five years was idiosyncratic, not cyclical: on January 22, 2024 ADM placed CFO Vikram Luthar on administrative leave, delayed its Q4 results, and disclosed inquiries into accounting in its Nutrition segment — the shares fell ~24% in a day and a governance discount entered the multiple. (4) Through 2024 and into April 2025 the operating downcycle did the rest, as soybean-crush spreads compressed against newly-built capacity and ethanol/sweetener margins softened, bottoming near $39 amid the broad April-2025 tariff selloff. (5) From there a ~95% rally was driven by improving biofuel-policy visibility (a constructive EPA Renewable Volume Obligation final rule and the 45Z clean-fuel production credit lifting renewable-diesel feedstock demand) and sequential margin recovery — a multiple re-rating that ran ahead of the earnings it anticipates.

1. Executive Summary

Archer-Daniels-Midland is one of the four global agricultural-commodity houses (the “ABCD” quartet, with Bunge, Cargill, and Louis Dreyfus). It originates, transports, stores, processes, and merchandises grains and oilseeds at enormous scale, organized into three segments: Ag Services & Oilseeds (AS&O — origination, soybean/oilseed crushing, global trading; ~77% of revenue, the cyclical engine), Carbohydrate Solutions (corn wet/dry milling, sweeteners, starches, ethanol; ~13% of revenue but ~37% of segment profit), and Nutrition (flavors, specialty and health-and-wellness ingredients, animal nutrition; ~9% of revenue). FY2025 revenue was $80.3B.

This is a structurally average business at a genuine earnings trough, whose stock has already re-rated as though the recovery has arrived. The investment facts that matter:

• No durable competitive advantage. ADM’s scale, ~270 processing plants, ~420 grain elevators and owned rail/barge/port logistics are real barriers to entry that sustain a stable oligopoly — but they confer no pricing power and no barrier to competition. Through-cycle ROIC is ≈7%, roughly equal to the cost of capital; it fell to 3.6% in FY2025. Economics do not improve with scale.
• A deep cyclical trough. Diluted GAAP EPS collapsed from a record $7.71 in FY2022 to $2.23 in FY2025 (−71%), driven by oilseed-crush segment profit falling from ~$4.4B to ~$1.6B as renewable-diesel-driven overbuilt crush capacity met soft demand. ADM’s adjusted EPS was $3.43; its FY2026 adjusted EPS guide is $4.15–4.70.
• The recovery is largely priced. At $76.79 (~$35B market cap, ~$45B EV) on trough earnings, the multiple optics are extreme (34× trailing GAAP EPS, 17× trailing EBITDA) precisely because the denominator is depressed. Normalize to mid-cycle and the stock trades ~12–13× and ~9–10× EV/EBITDA — fair, not cheap. The ~95% rally off the April-2025 low has been almost entirely multiple repair.
• Mediocre capital allocation and a governance scar. Management repurchased ~$6.5B of stock in FY2022–24 at $70–90 and bought nothing at the FY2025 trough; the Nutrition roll-up (anchored by the $3B WILD Flavors deal) produced flat, sub-WACC profit and was the locus of the 2024 intersegment-accounting matter (CFO departure, material weakness — since remediated — and SEC/DOJ scrutiny). Insiders are net sellers; the lone recent conviction buy is a ~$487K director purchase in February 2026.
• Cushioned downside. A 52-year Dividend King yielding ~2.7%, investment-grade balance sheet (net debt ~$7.4–8.7B, ~2.8× trough EBITDA), and trough-level earnings limit the drawdown. This is a hold-and-collect cyclical, not a compounder and not a short.

The remainder of this memo argues each of these points from the filings and the numbers. It takes no position and sets no price target; the single view is fenced in Claude’s Take above.

2. Business Overview

ADM, founded in 1902 and headquartered in Chicago, is in the business of moving and transforming agricultural raw materials. Its economic role is that of a midstream toll-taker and merchant sitting between farmers and the food, feed, fuel, and industrial end-markets: it buys crops at the farm gate or country elevator, stores and transports them through an owned logistics network, processes them into intermediate products (vegetable oil and protein meal, ethanol and sweeteners, flavors and ingredients), and sells them on — capturing processing spreads (e.g., the soybean “crush” margin between the cost of beans and the combined value of oil and meal) and merchandising/trading margins. It is one of the largest such houses in the world.

Segment structure (FY2025, segment operating profit basis; source: FY2025 10-K, Note 17):

Two facts jump out of this table. First, revenue mix and profit mix diverge sharply: AS&O is 77% of revenue but under half of segment profit, while Carbohydrate Solutions is ~13% of revenue and ~37% of profit — corn processing (sweeteners, starches, ethanol) is structurally a higher-return business than oilseed merchandising. Second, the entire earnings decline since 2022 is a margin/spread event, not a volume collapse: total segment profit fell from ~$6.55B (FY2022) to ~$3.24B (FY2025), driven overwhelmingly by AS&O’s oilseed-crush profit.

• Ag Services & Oilseeds. The cyclical heart of ADM. Ag Services originates and merchandises grains and oilseeds globally and operates ADM’s transportation assets (river barges, rail, export terminals). Crushing turns soybeans, canola, and soft seeds into vegetable oil (food, feed, and increasingly biodiesel/renewable-diesel feedstock) and protein meal. Refined Products and Other refines oils and produces biodiesel. This segment also houses ADM’s equity-method stake in Wilmar International (~22%), a large Asian agribusiness — a material but non-operating, lag-reported source of “earnings.”
• Carbohydrate Solutions. Corn (and wheat) wet and dry milling into sweeteners (high-fructose corn syrup, dextrose, glucose), starches, flour, and ethanol (fuel and industrial/USP-grade alcohol). More domestically anchored and somewhat less spread-volatile than oilseeds, with a meaningful tie to fuel-ethanol economics and exports.
• Nutrition. The intended growth/differentiation engine: flavors (built on the 2014 WILD Flavors acquisition), specialty proteins and texturants, health-and-wellness ingredients (probiotics, fibers), and animal nutrition (feed, additives). Sold to CPG, foodservice, and feed customers; in principle a stickier, higher-margin, recipe-embedded business. In practice it has under-delivered (see below).

Revenue quality. The vast majority of ADM’s revenue is commodity-price flow-through — when corn and soybean prices fall, ADM’s revenue falls even if volumes and margins are flat. There is a recurring, contractual element in parts of Nutrition (flavor/ingredient supply agreements) and in some Carbohydrate Solutions sweetener/starch contracts, but ADM is fundamentally a spread-and-volume business, not a recurring-revenue business. Its profit is the thin slice (gross margin ~6%) captured on a vast tonnage of throughput.

Verdict: A genuinely essential, globally-scaled midstream agribusiness — but one whose profit is a thin, spread-dependent margin on commodity throughput, with the bulk of earnings (and all of the earnings volatility) concentrated in oilseed crushing.

3. Industry Dynamics

Structure: a concentrated oligopoly with no pricing power. Global grain and oilseed origination and processing is dominated by the ABCD quartet plus a handful of regional and integrated players (Wilmar, COFCO, Glencore Agriculture/Viterra). Concentration is high, and the assets — port terminals, crush plants, elevator networks, barge fleets — represent real barriers to entry: a new entrant cannot cheaply replicate ADM’s North American logistics footprint. But concentration here does not create pricing power. The products (vegetable oil, meal, ethanol, sweetener) are fungible commodities priced off exchange-traded references (CBOT soybeans, soybean oil, corn). ADM is a price-taker on both its inputs and its outputs; what it earns is the spread between them, set by the supply/demand balance of processing capacity versus crop availability and end-market demand — not by ADM’s market position.

The margin cycle and its biofuel dependency. ADM’s profitability is governed by three spreads, all currently cyclically depressed off 2022 peaks:

• Soybean/oilseed crush margin — the dominant swing factor. It boomed in 2021–23 on tight oilseed balances and surging soybean-oil demand from the U.S. renewable-diesel (RD) build-out, then compressed sharply in 2024–25 as a wave of new crush capacity (industry crush capacity rose on the order of low-double-digit percent since 2023 on the RD thesis) came online into demand that stalled when biofuel policy stumbled. Soybean-oil stocks built and meal gluted.
• Ethanol margin — tied to corn cost, gasoline blending demand, and exports; volatile, periodically loss-making, structurally mature in the U.S.
• Sweetener/starch margin — the steadiest of the three, supported by oligopolistic domestic wet-milling.

The biofuel-policy dependency is the single most important external variable for ADM’s earnings and for its stock. Renewable-diesel and SAF demand is the secular driver that justified the crush-capacity build; the 45Z Clean Fuel Production Credit (which replaced the blender’s tax credit) and the EPA’s Renewable Volume Obligations determine how much of that demand actually materializes and who captures it. The 2025–26 stock rally is, in large part, the market pricing a more constructive reading of these rules. This is genuine upside optionality — but it is policy-dependent, industry-wide (ADM does not uniquely capture it), and outside management’s control.

The capital cycle (Marathon lens). Oilseed crushing is, by the supply-side framework, in or near the oversupply phase: high mid-cycle returns in 2021–23 attracted capital, the industry built capacity, and returns are now mean-reverting below mid-cycle as that capacity competes for throughput against soft demand. Marathon’s asset-growth anomaly — capacity additions presaging poor forward returns — argues for caution on the durability of any near-term margin recovery until the over-build is digested. The bullish counter is that RD/SAF demand growth eventually absorbs the capacity; the bearish read is that capacity is sticky and spreads stay compressed for longer than the +95% stock move assumes.

Competitive shift: Bunge-Viterra. The most important structural event in ADM’s competitive landscape is the completion of the Bunge–Viterra merger (closed July 2, 2025, ~$34B), creating a stronger, more globally-diversified #2 with deeper origination (Viterra’s grain-handling network) bolted onto Bunge’s processing. This does not threaten ADM’s existence, but it narrows ADM’s scale lead and intensifies competition for crops and crush spreads — a marginal negative for ADM’s competitive position, arriving precisely as the cycle is soft.

Verdict: structurally a bad industry for earning excess returns. It is essential, defensive in demand terms, and protected by entry barriers — but it is capital-intensive, deeply cyclical, devoid of pricing power, and acutely exposed to policy. The oligopoly preserves the players; it does not let them earn durably above their cost of capital.

4. Competitive Position

Name the moat: scale + asset-network + logistics cost advantage — a barrier to entry, not to competition. In Greenwald’s taxonomy, ADM’s advantage is a combination of (i) economies of scale in fixed-cost-heavy processing and a continent-spanning logistics network, and (ii) a modest cost advantage from owning the cheapest path (river barge, owned rail, export terminals) to move bulk commodities from the U.S. interior to export. These are real and durable enough that the ABCD structure has been stable for decades — new entrants do not appear, and market shares among the incumbents are relatively stable (Greenwald’s market-share-stability test for a genuine advantage is broadly satisfied at the industry-incumbent level).

But the decisive test fails: the advantage does not convert into durable excess returns. A moat exists only if a financial outcome would deteriorate without it. ADM’s barriers protect it from new entrants but not from each other — the ABCD players compete away the spread, and the binding constraint on profitability is the commodity cycle, not competitive positioning. The proof is in the returns:

Through-cycle ROIC averages ≈7% — and ADM’s own disclosed trailing-four-quarter Adjusted ROIC of ~6.3% sits below its ~8% cost of capital. A business whose best years (peak ROIC ~10%) only modestly clear WACC, and whose trough years destroy economic value, does not have a competitive advantage in the sense that matters to an owner. It has a competitive position — durable, but not value-creating across the cycle.

Nutrition: the differentiation that wasn’t. ADM spent more than a decade and ~$5B+ trying to build a higher-margin, less-cyclical Nutrition franchise (WILD Flavors $3B in 2014, plus Neovia, Protexin, and numerous bolt-ons) precisely to escape the commodity trap. The result: a segment earning a ~5–6% operating margin with flat profit (~$0.42B FY2025 vs ~$0.74B at the 2022 peak), well below the multiples ADM paid implied, and — critically — the locus of the 2024 intersegment-accounting matter (alleged adjustments that inflated Nutrition’s reported profit, a metric that fed executive incentive comp). This is value destruction dressed as diversification, and it removes the one credible argument that ADM is more than a commodity processor.

Versus peers. Bunge (post-Viterra) is now a comparably-scaled, arguably better-positioned global crusher/merchant; Ingredion is a smaller, higher-margin, more specialty-tilted starch/sweetener business that earns structurally higher ROIC than ADM precisely because it is less commodity-exposed. ADM’s relative edge is its North American logistics and origination depth; its relative weakness is the absence of a high-return specialty engine that actually works.

Verdict: a crowded oligopoly with strong barriers to entry but weak differentiation and no durable pricing power. ADM earns roughly its cost of capital through the cycle. The “moat” keeps the club exclusive; it does not make membership lucrative.

5. Growth History and Forward Opportunities

Historical “growth” is mostly commodity-price flow-through. ADM’s reported revenue swung from $64.4B (FY2020) to $101.6B (FY2022) to $80.3B (FY2025) — a path dictated by corn and soybean prices, not by underlying value creation. Volumes have grown modestly; profit has been a cycle, not a trend, peaking at $4.34B net income (FY2022) and troughing at $1.08B (FY2025). Over the five years FY2020–FY2025, diluted EPS went $3.15 → $4.79 → $7.71 → $6.43 → $3.65 → $2.23 — the signature of a cyclical, not a compounder.

Organic vs. acquired. What secular growth ADM has pursued came through acquisition, concentrated in Nutrition — and, as the sections below detail, that acquired growth produced flat segment profit and sub-WACC returns. Organic volume growth in the core processing business is low-single-digit and GDP/population-linked; the topline is dominated by price.

Forward opportunities — real optionality, but not proprietary or near-term:

• Biofuels / renewable-diesel & SAF feedstock. The most consequential. Rising RD and sustainable-aviation-fuel demand pulls soybean oil into fuel and supports crush spreads; ADM’s crush and refining assets are positioned to benefit. But this is an industry tailwind that ADM shares with every crusher, and its magnitude is set by policy (45Z, RVO), not by ADM.
• Flavors / health-and-wellness ingredients. A genuine secular demand trend (clean-label, plant protein, probiotics) — but in a segment ADM has struggled to monetize at attractive returns.
• Decarbonization / carbon capture (CCS) and 45Z credits. ADM’s ethanol/processing footprint plus carbon-sequestration projects could earn incremental policy-driven credits; early-stage and policy-contingent.
• Cost and productivity programs. Management has guided to multi-hundred-million-dollar cost reductions and portfolio simplification — a self-help lever that is real but defensive (protecting trough earnings), not growth.

Verdict: low-quality growth. The topline is commodity flow-through; the acquired growth (Nutrition) did not earn its cost of capital; and the credible forward drivers (biofuels) are industry-wide and policy-dependent rather than ADM-specific secular compounding. The investable thesis is cyclical normalization, not growth.

6. Financial Quality

Razor-thin, cyclical, commodity-processor economics. ADM converts ~$80B of revenue into ~$5B of gross profit (gross margin ~6.3% in FY2025) and, at the trough, ~$1.4B of operating income (operating margin ~1.8%). COGS is ~94% of sales. On that structure, small moves in processing spreads swing net income violently — which is exactly what the five-year record shows:

The FY2025 trough is overwhelmingly an oilseed-crush story: AS&O segment operating profit fell to ~$1.6B from ~$4.4B at the 2022 peak, with crush specifically collapsing on compressed spreads. Carbohydrate Solutions (~$1.2B) and Nutrition (~$0.42B) held comparatively flat.

Adjusted vs. GAAP — a 54% gap. ADM reports an Adjusted EPS of $3.43 for FY2025 against GAAP diluted EPS of $2.23 — a $1.20 (54%) gap bridged by “specified items” (~$236M in FY2025, ~$490M in FY2024) that are largely impairments and restructuring. These are recurring-in-nature for a perpetually-restructuring commodity processor, so the adjusted figure should be treated as a generous representation of earning power, not a clean one. Even on adjusted EPS, the FY2026 guide of $4.15–4.70 implies a business earning roughly its cost of capital, not above it.

The cash-flow trap. ADM’s operating cash flow is inversely correlated with the commodity cycle and is a poor proxy for earnings power. When prices fall, inventory liquidates and working capital releases cash; when prices rise, working capital absorbs cash. The record is stark:

FY2025’s headline OCF of $5.45B (5.1× net income) was flattered by a +$2.76B working-capital release — inventory and receivables shrinking as commodity prices fell. This is liquidation cash, not earning power; it reverses when the cycle turns up (note FY2020’s −$2.4B OCF on a working-capital build). Capex is modest and disciplined (~$1.3–1.5B/yr), so “free cash flow” optically looks enormous at the trough — but a fair read of normalized FCF strips the working-capital swing and lands well below the headline. Do not capitalize trough OCF.

Balance sheet: sound, investment-grade. Total borrowings (incl. leases) ~$9.8B against ~$1.0B cash; standard net debt is ~$7.4B (FY2025), down from ~$9.5B (FY2024) as the inventory-liquidation cash paid down short-term debt. Net debt is ~2.8× trough EBITDA and ~0.3× equity — comfortable. ADM emphasizes a still-more-favorable “RMI-adjusted net debt” framing that nets readily-marketable (exchange-hedged) inventories; that is a defensible commodity-trader convention but flatters the optics. Tangible book is positive but eroded by ~$4.8B goodwill and ~$6.7B intangibles (largely Nutrition). Current ratio ~1.37×.

A buried QoE item — the Wilmar stake. ADM’s ~22% equity-method interest in Wilmar International is carried at ~$4.0B versus a market value ~$3.4B — i.e., ~15% underwater and not impaired (it drew an auditor Critical Audit Matter after a $461M FY2024 impairment). Wilmar contributes a material, lag-reported, non-operating and largely non-cash slice of ADM’s reported earnings (including, in some periods, one-time remeasurement gains). Investors should mentally separate this from ADM’s operating cash earnings.

Verdict: low-quality, deeply cyclical economics that do not improve with scale. The business is sound and well-financed, but its margins are structurally thin, its returns sit near cost of capital at best, its adjusted earnings are generously stated, and its cash flow is a cyclical mirage at the trough. Quality of the balance sheet is good; quality of the earnings is poor.

7. Capital Allocation

Verdict up front: below-average over the cycle, with two clear self-inflicted errors partially offset by a sound dividend and prudent restraint on a mega-deal.

Error 1 — pro-cyclical buybacks. ADM repurchased stock aggressively into strength and stopped into weakness — the opposite of value-accretive timing:

Roughly $6.45B was spent in FY2022–24 at $50–90/share, and zero was repurchased in FY2025 when the stock bottomed near $39 — its cheapest level of the cycle. Diluted share count did fall meaningfully (566M in FY2020 to ~484M in FY2025), so the buyback reduced the count, but it did so by buying high and abstaining low. That is value-destructive sequencing from a management team that should understand its own cyclicality better than anyone.

Error 2 — the Nutrition roll-up. Over a decade ADM deployed ~$5B+ into Nutrition (WILD Flavors ~$3B in 2014 the anchor) to build a higher-multiple business. The segment earns a ~5–6% margin, generated flat profit, returns below WACC, and became the subject of the 2024 accounting matter — the very ROIC/segment-profit metric used in incentive comp was the one manipulated. By any honest reckoning this capital was not intelligently allocated.

Offsets — genuine but partial:

• Dividend: the crown jewel. ADM is a Dividend King with 50+ consecutive years of increases, currently ~$2.05/share (~2.7% yield), ~$0.99B/yr. The FY2025 payout ratio of ~92% on GAAP EPS is a trough artifact (it is comfortably covered on adjusted earnings and normalized cash flow); the dividend is not at risk. This is the most reliable element of ADM’s capital-return story and the backbone of the ownership case for income-oriented holders.
• Incentive design is better than most — but compromised. ADM’s long-term incentive plan uses a genuine Adjusted-ROIC hurdle (~50% weight), which is more rigorous than the revenue/EPS-only plans common among peers, and it flexed down in the downcycle (LTI paid ~62%, annual incentive ~45% of target). The fatal caveat: Adjusted ROIC is the metric the 2024 matter alleged was manipulated, so the governor only works if the inputs are clean.
• Restraint on the mega-deal. ADM did not chase a Bunge/Viterra-scale acquisition into a soft cycle — a defensible decision that preserved the balance sheet.

Insider behavior (Form 4 corpus, ~600 filings parsed): mildly negative. Over ~5 years there were only three open-market purchases — CEO Juan Luciano ~$1.0M (Jul-2021), a token 5-share CFO buy, and director David McAtee ~$487K at $64.90 (Feb-5-2026), the lone recent conviction signal — against $75M+ of insider sales, including Luciano’s ~$19.7M (Aug–Sep 2024, 10b5-1-planned) into post-scandal weakness. The new CFO has no purchase on record. There is no deep-value insider buying cluster of the kind that would corroborate a contrarian bottom.

Verdict: management has not allocated capital intelligently across the cycle. The dividend and incentive design are creditable; the buyback timing and the Nutrition roll-up are not, and the governance lapse that the comp metric enabled is a real mark against the team.

8. Changes and Headwinds — Last Two Years

The two years to mid-2026 have been the most eventful in ADM’s recent history, dominated by one governance shock and one cyclical downturn, with a policy-driven recovery layered on top.

• The 2024 accounting matter (the defining event). On January 21–22, 2024, ADM placed CFO Vikram Luthar on administrative leave, delayed its Q4 2023 results, and disclosed an internal investigation (with an SEC document request) into accounting practices for intersegment sales in the Nutrition segment. The shares fell ~24% in a day. The investigation found that certain segment-level results had been mis-stated (consolidated results were not materially affected), ADM filed a Form 10-K/A revising segment disclosures (Nov-2024), identified a material weakness in controls over segment reporting, and faced SEC and DOJ scrutiny plus securities and derivative litigation. Resolution status: ADM reports the material weakness was fully remediated as of June 30, 2025, with disclosure controls assessed effective at December 31, 2025; Luthar departed and Monish Patolawala was appointed CFO (2024). Open item: the final terms/closure of the SEC/DOJ matter and related litigation should be tracked (see Open Questions).
• Oilseed-crush downcycle. From 2024 into early 2025, soybean-crush spreads compressed against newly-built capacity and soft renewable-diesel pull (policy uncertainty around the 45Z transition), driving AS&O profit down by more than half from its peak and dragging FY2025 EPS to the $2.23 trough. Q1-2026 crushing was still running at a small operating loss (ex-mark-to-market) on the segment basis — the recovery is early.
• Biofuel-policy inflection (the recovery catalyst). Improving visibility on the EPA’s Renewable Volume Obligations and the 45Z Clean Fuel Production Credit in late-2025/early-2026 lifted RIN values and renewable-diesel feedstock demand, supporting a sequential crush/ethanol recovery and powering the stock’s ~95% rebound. This is the bull case’s engine — and its key vulnerability, being policy-set.
• Bunge–Viterra close (July 2025). A structurally stronger competitor (see below).
• Cost / portfolio actions. Management has announced cost-reduction and simplification programs (multi-hundred-million-dollar targets, headcount and footprint actions) to defend trough margins.

Verdict: net negative-to-neutral for the thesis. The downcycle and the governance scar are weakening developments; the policy-driven margin recovery is a genuine positive but is already substantially reflected in the price. On balance the last two years have lowered ADM’s quality perception (governance, Nutrition) while the cyclical setup has merely normalized off a trough.

9. Risk Analysis

The dominant risks are cyclical and valuation-driven, not existential. The base-rate danger is not that ADM blows up — it won’t — but that crush margins stay soft while the stock has already paid for a recovery, leaving a multi-year dead-money outcome with the dividend as the only return.

10. Valuation Discussion (Embedded Expectations)

The headline multiples are distorted by trough earnings and must be normalized. At $76.79 (~$35B market cap, EV ~$45.3B):

• Trailing GAAP P/E ~34× and EV/EBITDA ~17.3× look expensive — but both denominators (EPS $2.23, EBITDA $2.6B) are at the cycle trough. These optics are why own-history percentile screens flag a “rich” P/E (98th percentile) — a classic cyclical artifact, not a valuation signal. The more reliable own-history reads are P/B 1.62× (≈87th percentile) and P/S 0.46× (≈91st percentile) — both genuinely elevated versus ADM’s own range (the stock has typically traded ~1.2–1.5× book), confirming the stock is not cheap on the metrics that survive trough distortion.
• EV/Sales ~0.56× is meaningless in isolation for a ~6%-gross-margin merchant.

Embedded expectations — what the price requires. Normalize to mid-cycle. ADM’s mid-cycle EBITDA is roughly $4.0–4.5B and mid-cycle EPS roughly $5.00–6.00 (the 2020–2025 average diluted EPS is ~$4.66, skewed up by the 2022–23 peak; a forward mid-cycle in the low-to-mid $5s is reasonable). On those:

• At $77, EV/normalized EBITDA is ~10× and P/normalized EPS is ~13–14× — fair-to-slightly-rich for a no-growth, cost-of-capital-return commodity processor that has historically traded ~10–13× mid-cycle.
• Crucially, ADM’s own FY2026 adjusted-EPS guide is $4.15–4.70 — below the ~$5.50–6.00 the current price implies. The market is paying today for a mid-cycle that management is not yet guiding to. That is the core of the “recovery bought before it arrived” framing.

Scenario analysis (illustrative; not a price target):

The base case clusters around $60–68, below the current $77 — i.e., on a sober mid-cycle the stock is already fair-to-slightly-rich, with the bull case needed to justify the price. The asymmetry from $77 is unattractive: the bear ($38–44) is a ~45% drawdown, the bull ($80–90) a ~15% gain. The skew was favorable at $39; it is unfavorable at $77.

No price target and no recommendation — this section frames embedded expectations only; the single view is in Claude’s Take.

11. Variant Perception

Consensus. Sell-side has turned constructive on the recovery (representative: Buy ratings with price targets in the mid-$90s; FY2026 EPS expected up sharply off the trough). The consensus narrative: trough is in, biofuel policy is turning, crush normalizes, ADM is a cheap-on-normalized-earnings Dividend King with buyback optionality.

Strongest bull case. (1) FY2025 is a cyclical trough, not a structural impairment — crush and ethanol spreads mean-revert. (2) Biofuel policy (45Z, RVO) is structurally constructive and pulls soybean oil into fuel for years. (3) ADM is a fortress-balance-sheet Dividend King; downside is cushioned and you are paid ~2.7% to wait. (4) On normalized earnings the stock is reasonable, and a buyback restart plus cost-out add upside. (5) The factor profile (low-beta value/dividend) means limited downside volatility.

Strongest bear case. (1) Structural oilseed-crush over-capacity from the 2021–24 RD build-out keeps spreads compressed longer than the rally assumes (Q1-26 crush still ~breakeven). (2) Bunge-Viterra is now a stronger competitor for the same crops and spreads. (3) Nutrition value destruction + the accounting overhang undercut the “more than a commodity” thesis and the credibility of management’s own return metrics. (4) ROIC stuck at ~6.3% < WACC — this is a value-neutral business that compounds book value slowly at best. (5) The +95% rally already prices the recovery — the easy multiple-repair money is made, and from $77 the risk/reward is skewed down (base case ~$60–68).

The 3–5 assumptions that decide it:

1. Do soybean-crush spreads durably widen, or does over-capacity cap them? (The single most important variable.)
2. Does 45Z/RVO policy deliver the RD/feedstock demand the build-out assumed?
3. Is mid-cycle EPS ~$4 (bear), ~$5 (base), or ~$6+ (bull)?
4. Does ADM’s Adjusted ROIC climb back toward double digits, or stay ≈WACC?
5. Is the governance/accounting chapter fully closed, or is there a tail (SEC penalty, litigation, fresh control issue)?

Falsification. The bull breaks if FY2026 adjusted EPS prints below ~$4.15, crush rolls back over in 2H-2026, or China offtake fails to normalize. The bear breaks if margins hold through 2027 with Adjusted ROIC climbing to double digits and a buyback executing into the strength.

Factor-positioning read (overlay, not a call). ADM is a low-beta (0.33) Value + DividendYield name that was abandoned and has re-rated: y1 total return ~+51% and m6 strongly positive, but y5 only ~+7.8%/yr and a lifetime ~−68% max drawdown. The tape says momentum-up off a washed-out base — not a falling knife, not a crowded momentum trade. Read through the variant-perception lens, that supports the view that the de-rating reversal is largely spent, and the next leg requires mid-cycle EBITDA to actually materialize rather than further multiple expansion. Consensus is no longer offsides bearish (as it was at $39); if anything it is now mildly offsides optimistic relative to ADM’s own FY2026 guide.

12. Fact vs. Interpretation

13. Open Questions

1. SEC/DOJ closure. What are the final terms (penalty, undertakings) of the SEC/DOJ matter, and is the related securities/derivative litigation resolved? The material weakness is remediated, but the enforcement chapter’s closure is not confirmed in the public record reviewed.
2. Crush-margin trajectory. Will soybean-crush spreads widen durably in 2H-2026 and 2027, or does over-capacity cap them near breakeven? (Q1-2026 crush was still ~breakeven.)
3. 45Z/RVO final economics. How much RD/SAF feedstock demand will the finalized 45Z credit and RVO actually deliver, and how much accrues to ADM versus being competed away?
4. Mid-cycle EPS. Is the right normalized number ~$4, ~$5, or ~$6+? This single estimate determines whether $77 is cheap, fair, or rich.
5. Buyback restart. Will management restart repurchases — and if so, will they finally buy counter-cyclically, or repeat the buy-high pattern?
6. Wilmar. Will the stake be impaired further, monetized, or held? It is a ~$4B non-core, non-operating asset distorting reported earnings.
7. Nutrition strategy. Fix, shrink, or divest? Management’s commitment to the segment after the scandal is unclear.

14. What Must Be True

For the bull case to be right (ADM is cheap at $77 and worth $80–90+):

• Soybean-crush and ethanol spreads must mean-revert toward long-run averages and hold through 2026–27, lifting AS&O profit back toward $3B+.
• Biofuel policy (45Z, RVO) must deliver durable RD/SAF feedstock demand that ADM meaningfully captures.
• FY2026 adjusted EPS must reach the upper half of the $4.15–4.70 guide and inflect toward ~$5.50–6.00 in FY2027, with Adjusted ROIC climbing back toward double digits.
• Falsification test: FY2026 adjusted EPS prints below ~$4.15, or 2H-2026 crush spreads re-compress, or China offtake fails to normalize. Any of these breaks the bull case.

For the bear case to be right (ADM is fair-to-rich at $77, base value $60–68, risk to $38–44):

• Oilseed-crush over-capacity (post-RD build-out) must keep spreads compressed near breakeven for longer than the rally assumes.
• Mid-cycle EPS must prove to be ~$4 (not ~$5–6), leaving the stock at ~18–20× mid-cycle — expensive for a cost-of-capital business.
• ROIC must stay ≈WACC, confirming ADM as a value-neutral cyclical, with the +95% move having front-run earnings that don’t fully arrive.
• Falsification test: crush margins hold through 2027 with Adjusted ROIC reaching double digits and a counter-cyclical buyback executing — that would break the bear case and validate a durable re-rating.

15. Source Appendix

See Appendix B — Source Appendix below for the full citation list (SEC filings, public market data, and public industry/policy sources).

This article takes no position and sets no price target. The single subjective view is fenced in “Claude’s Take” at the top. 2026-06-26.

APPENDIX A — Standard Diligence Questionnaire

Archer-Daniels-Midland Company (NYSE: ADM) — as of 2026-06-26. Supplemental to the research memo. Labels: F = Fact, I = Interpretation, A = Assumption.

General

What thoughtful questions have other investors asked about this company? The sharpest investor questions cluster on five points: (1) Is FY2025 a cyclical trough or a structural impairment of crush economics? — the single biggest debate (I). (2) What is true mid-cycle EPS — ~$4, ~$5, or ~$6+? — the answer decides whether $77 is cheap, fair, or rich (I). (3) Is the 2024 Nutrition accounting matter fully closed, and can management’s own ROIC metrics be trusted? (F/I). (4) Will biofuel policy (45Z, RVO) deliver the renewable-diesel demand the crush build-out assumed, and does ADM capture it or compete it away? (I). (5) Will management restart buybacks counter-cyclically, or repeat the buy-high pattern? (I).

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? A clear cyclical low (F). GAAP diluted EPS fell from a record $7.71 (FY2022) to $2.23 (FY2025), −71%, driven by oilseed-crush spread compression. Adjusted EPS $3.43; FY2026 adjusted guide $4.15–4.70 — recovering off the trough but not yet mid-cycle (F).

Driven by the external environment or internal actions? Overwhelmingly external — processing spreads (crush, ethanol, sweetener) set by global crop balances, biofuel policy, and competitor capacity (I). Internal actions (cost-out, portfolio simplification) are defensive, second-order.

How stable are revenues? Unstable in dollars (commodity-price flow-through: $64B→$102B→$80B across FY20–25) but underlying volumes are relatively stable; the volatility is in price and, more importantly, in spreads (F/I).

Outlook for products/services? Demand is defensive (food, feed, fuel) and population/GDP-linked; the growth wildcard is biofuel/renewable-diesel feedstock demand, which is policy-dependent (I).

How big will this market be — growing, shrinking, domestic or international? Large, global, low-single-digit-growth in volume terms; the addressable profit pool expands with biofuel adoption but is shared across the ABCD oligopoly + Wilmar/COFCO (I).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Marginally more — Bunge-Viterra (closed Jul-2025, ~$34B) creates a stronger #2, and post-RD-build-out crush over-capacity intensifies competition for spreads (F/I).

How profitable is the business (ROIC, ROE)? Low and cyclical: ROIC 3.6% (FY2025 trough), ~7% through-cycle, ~10% at peak; ROE 4.3%/16.9% trough/peak. ADM’s own Adjusted ROIC ~6.3% sits below its ~8% WACC (F).

How profitable is the industry — competitors, barriers to entry? Capital-intensive, thin-margin (ADM gross margin ~6%). Strong barriers to entry (logistics networks, port/crush assets) but no barrier to competition — the ABCD members compete spreads away (I).

Can the business be easily understood? Conceptually yes (buy crop, process, sell spread); in detail no — segment accounting, hedging/mark-to-market, equity-method Wilmar earnings, and RMI-adjusted leverage make the financials genuinely hard to read (I).

Can it be undermined by foreign low-cost labor? Not labor — it is asset/logistics-intensive, not labor-intensive. The relevant competitive threat is foreign agribusiness scale (Wilmar, COFCO, Bunge-Viterra), not low-cost labor (I).

Do brands matter? Minimal — ADM sells commodities and B2B ingredients; brand matters only modestly in parts of Nutrition (flavors), which has under-performed (I).

Nature of competition? Spread/cost competition among a stable oligopoly; the binding constraint is the commodity cycle, not share battles (I).

Customers’ switching costs? Low for commodity products; modestly higher for embedded flavor/ingredient formulations in Nutrition (I).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? The owned logistics network (river/rail/port) carries decades of accumulated depreciation (gross PP&E ~$31.5B vs net ~$12.5B) — replacement value exceeds book (I). The Wilmar stake is carried at equity (~$4.0B) (F).

Off-balance-sheet liabilities? Operating commitments, purchase obligations, and substantial derivative/hedging positions; nothing identified as an undisclosed material liability in the corpus reviewed (I).

How conservative is the accounting? A concern. The 2024 intersegment-accounting matter (material weakness, since remediated) is direct evidence of past aggressiveness in segment reporting; Adjusted EPS runs ~54% above GAAP on recurring-in-nature add-backs; the Wilmar stake is carried ~15% above market without impairment (F/I).

How CapEx-hungry is the business? Moderately — capex ~$1.3–1.5B/yr (~1.5–2% of sales), manageable, with the asset base mature (F).

Capital Allocation & Management

How much FCF, and how is it used? Headline FCF is large but cyclically distorted — FY2025 OCF $5.45B was flattered by a +$2.76B working-capital release (inventory liquidation); FY2020 OCF was −$2.4B on a build (F). Normalized FCF is well below the trough headline. Uses: dividends (~$1.0B/yr), buybacks (cyclically), bolt-on M&A, capex.

Significant acquisitions recently? No large recent deals; the legacy concern is the ~$5B+ Nutrition roll-up (WILD Flavors $3B/2014 anchor) that earned sub-WACC returns (F/I).

Buying back shares? Yes, but pro-cyclically — ~$6.45B in FY2022–24 at $50–90, and $0 in FY2025 at the ~$39 trough. Share count fell 566M→484M (FY20–25) but via poor timing (F).

Issuing large amounts of stock to insiders? No — SBC is modest (~$83M FY2025) for a company this size (F).

Compensation policy / incentive alignment? Better-than-peer design (Adjusted-ROIC LTI hurdle, ~50% weight, flexed down in the downcycle) but compromised by the fact that the ROIC/segment metric was the one manipulated in 2024 (F/I).

Motivations of management? CEO Juan Luciano (long-tenured); incentive metrics are returns-based but were the subject of the accounting matter. Insiders are net sellers (~$75M+ sales vs 3 open-market buys in 5 years; the lone recent conviction buy a ~$487K director purchase Feb-2026) (F).

Valuation & Market Data

ADR, MLP, or K-1 issuer? No — a standard U.S. C-corp common stock; no K-1 (F).

Dividend policy? A Dividend King — 50+ consecutive years of increases, ~$2.05/share, ~2.7% yield. FY2025 GAAP payout ~92% is a trough artifact; covered on adjusted earnings and normalized cash flow (F/I).

How profitable is the business? Low-return through the cycle (ROIC ≈ WACC); see above (F).

Net income diverging from cash from operations? Yes, structurally and cyclically — OCF is inversely correlated with commodity prices via working capital, so it diverges from NI in both directions (FY2025 OCF 5.1× NI on a liquidation; FY2020 OCF negative on a build). Treat OCF with caution (F/I).

Risks & Downside

What factors would cause the stock to decline? Crush/ethanol spreads re-compressing; biofuel policy disappointing; mid-cycle EPS proving to be ~$4 not ~$5–6; a reopening of the governance/accounting matter; China/tariff disruption; or simply the realization that the +95% rally front-ran earnings (I).

Risk of a catastrophic loss? Very low — investment-grade balance sheet, diversified essential-goods franchise (I).

Chance of a total loss? Negligible (I).

Recent News & Events

Has the business environment changed recently? Yes — (1) biofuel-policy inflection (RVO final rule, 45Z) supporting a crush/ethanol recovery and the stock’s ~95% rebound; (2) Bunge-Viterra close (Jul-2025); (3) the 2024 accounting matter’s resolution (material weakness remediated by Jun-2025) (F).

Significant acquisitions? None material recently (F).

Change in accounting policies? The 2024 restatement of segment disclosures (consolidated unaffected) and subsequent controls remediation (F).

Recent management/market changes? New CFO Monish Patolawala (2024, replacing Vikram Luthar); ongoing cost-reduction/portfolio-simplification programs (F).

APPENDIX B — Source Appendix

Archer-Daniels-Midland Company (NYSE: ADM) — research initiation, 2026-06-26. Public primary sources first.

Primary — SEC Filings (CIK 0000007084)

1. ADM Form 10-K, FY2025 (filed 2026-02-17; adm-20251231) — segment revenue/operating profit (Note 17), consolidated statements, internal-controls section (material-weakness remediation status), Adjusted EPS and Adjusted ROIC disclosures, Wilmar equity-method disclosure. https://www.sec.gov/Archives/edgar/data/7084/000000708426000011/adm-20251231.htm
2. ADM Form 10-K, FY2024 (filed 2025-02-20; adm-20241231) — prior-year comparatives, Wilmar impairment ($461M), specified items. https://www.sec.gov/Archives/edgar/data/7084/000000708425000011/adm-20241231.htm
3. ADM Form 10-K, FY2023 and Form 10-K/A (original 2024-03-12; amendment Nov-2024) — revised segment disclosures arising from the intersegment-accounting matter. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000007084&type=10-K
4. ADM Forms 10-Q (FY2024–FY2026 quarters) — quarterly segment trends, Q1-2026 crush results, FY2026 guidance.
5. ADM Form 8-K, January 22, 2024 — disclosure of CFO administrative leave, delayed Q4 results, and the internal/SEC investigation into Nutrition intersegment accounting.
6. ADM DEF 14A proxy statements (FY2023–FY2025) — executive compensation structure, Adjusted-ROIC long-term-incentive hurdle and payout outcomes.
7. ADM Forms 3/4/5 (insider transactions, 2021–2026) via SEC EDGAR — open-market purchases (CEO Luciano ~$1.0M Jul-2021; director McAtee ~$487K @ $64.90 Feb-2026) vs. sales (~$75M+, incl. Luciano ~$19.7M Aug–Sep 2024, 10b5-1).

Primary — Market & Financial Data (public)

8. ADM consolidated financials, FY2020–FY2025 + TTM — income statement, balance sheet, cash flow, and derived ratios (ROIC/ROE/margins, enterprise value, valuation multiples, per-share data), reconciled to the 10-K.
9. Daily price history — 5-year OHLCV, moving averages, and beta (0.33), used for the Five-Year Event Map and price levels (close $76.79, 2026-06-26; 5yr range $39.32–$86.70 adj; 52wk $49.77–$82.56).
10. Own-history valuation percentiles — P/E 34.3× (trough-distorted), P/B 1.62×, P/S 0.46× versus ADM’s own multi-year range.
11. Factor/risk model — style-factor loadings (Value, DividendYield), risk-adjusted return history (1-yr +51%, 5-yr +7.8%/yr, lifetime −68% max drawdown), beta/alpha.

Secondary — Industry, Policy & Peer Context

12. U.S. EPA — Renewable Fuel Standard / Renewable Volume Obligations final rule (2026), governing renewable-diesel/biofuel demand.
13. U.S. Treasury / IRS — Section 45Z Clean Fuel Production Credit guidance (transition from the blender’s tax credit).
14. Bunge Global SA — Bunge–Viterra merger completion (closed July 2, 2025, ~$34B), competitive-landscape context. Public Bunge IR/press releases.
15. USDA / industry data — U.S. soybean crush capacity additions, soybean-oil stocks, ethanol export volumes, crush-margin trends 2024–2026.
16. Peer reference points — Bunge (BG), Ingredion (INGR), Andersons (ANDE), Darling Ingredients (DAR).
17. Wilmar International (SGX) — market value of ADM’s ~22% equity-method stake (~$3.4B vs ~$4.0B carrying value).

Notes on Reliability

• For all financial line items, EDGAR and the 10-K are primary; aggregated third-party data was used as an accelerant and cross-check, reconciled to the filing. Where a third-party figure and the filing diverge, the filing governs.
• The elevated P/E percentile is discounted in the analysis as a trough-earnings artifact per the standard cyclicals caveat; P/B and P/S are the more reliable own-history reads.
• Net-debt figures: standard net debt ~$7.4B (FY2025); ADM additionally reports a management-favorable “RMI-adjusted” net debt that nets readily-marketable inventories — flagged as a presentation convention, not used as the headline.
• Management commentary (earnings calls, guidance) is treated as a hypothesis and validated against filings and external data.